{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:31:47Z","timestamp":1790796707089,"version":"4.1.0"},"reference-count":53,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      Anaplastic thyroid cancer (ATC) is a rare and highly aggressive malignancy with limited treatment options. Currently, the only US Food and Drug Administration\u2013approved targeted therapies for ATC are directed at\n                      <jats:italic toggle=\"yes\">BRAF V600E<\/jats:italic>\n                      mutations and\n                      <jats:italic toggle=\"yes\">NTRK<\/jats:italic>\n                      fusions. This study aimed to characterize the somatic pathogenic gene variant (PGV) landscape of ATC to identify additional potentially actionable pathways.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      We queried the American Association for Cancer Research Project GENIE database (v18.0) via cBioPortal for somatic PGVs in ATC tumors. This multi-institutional data set provides next-generation sequencing and clinical data across cancer types. Genes were grouped by pathway relevance: MAPK (\n                      <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">KRAS<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">NRAS<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">EIF1AX<\/jats:italic>\n                      ), PI3K\/Akt\/mTOR (\n                      <jats:italic toggle=\"yes\">PIK3CA<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">PTEN<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">mTOR<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">AKT1\/2\/3<\/jats:italic>\n                      ), homologous recombination deficiency (HRD), and mismatch repair (MMR).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 350 ATC tumor samples were analyzed. PGVs were identified in MAPK pathway genes in 57.7% of tumors, PI3K\/Akt\/mTOR pathway genes in 26.6%, HRD-associated genes in 8.0%, and MMR-associated genes in 3.7%. In total, 72.0% (252\/350) of tumors harbored at least one PGV in one or more of these potentially targetable pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Somatic PGVs in potentially targetable pathways were found in 72% of ATC tumors. Given the aggressiveness of ATC and the limited efficacy of current treatments, these findings support the rationale for biomarker-driven basket trials investigating the efficacy of targeted therapies in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-25-00655","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:59:10Z","timestamp":1773863950000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutically Targetable Mutational Landscape of Anaplastic Thyroid Cancer"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7602-3641","authenticated-orcid":true,"given":"Murtaza","family":"Qazi","sequence":"first","affiliation":[{"name":"Lankenau Medical Center, Wynnewood, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8633-8931","authenticated-orcid":true,"given":"Muhammad Danyal","family":"Ahsan","sequence":"additional","affiliation":[{"name":"Hospital of University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talar","family":"Telvizian","sequence":"additional","affiliation":[{"name":"Lankenau Medical Center, Wynnewood, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Laiacona","sequence":"additional","affiliation":[{"name":"Lankenau Medical Center, Wynnewood, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadir","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Cooper University Hospital, Camden, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"McHugh","sequence":"additional","affiliation":[{"name":"Lankenau Medical Center, Wynnewood, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.76"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/542358"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.wjorl.2018.05.006"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0944"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3362"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0164"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041061"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32548"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000823"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2025.0044"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0040"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0954579419001792"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27025"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14679"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0033"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0477"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050777"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.4019"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85271"},{"key":"e_1_3_7_22_2","article-title":"Impact of somatic mutations on survival outcomes in patients with anaplastic thyroid carcinoma","author":"Wang JR","unstructured":"Wang JR, Montierth M, Xu L, et al: Impact of somatic mutations on survival outcomes in patients with anaplastic thyroid carcinoma. JCO Precis Oncol 10.1200\/PO.21.00504","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu749"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0151"},{"key":"e_1_3_7_25_2","unstructured":"The AACR Project GENIE Consortium. AACR Project GENIE: Powering precision medicine through an international consortium. Cancer Discov 7:818-831 2017"},{"key":"e_1_3_7_26_2","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","author":"Heeke AL","unstructured":"Heeke AL, Pishvaian MJ, Lynce F, et al: Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol 10.1200\/PO.17.00286","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.15098"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab014"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030710"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-17-0266"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2009.01.013"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.2133"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.1646"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0273"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1076"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105579"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.81"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161212800626210"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-14-0158-T"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02889-y"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040830"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2154-T"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29055"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0606"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40463-022-00594-6"},{"key":"e_1_3_7_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13829"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100049"},{"key":"e_1_3_7_48_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.880643"},{"key":"e_1_3_7_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab169"},{"key":"e_1_3_7_50_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4070"},{"key":"e_1_3_7_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103597"},{"key":"e_1_3_7_52_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2021-0632-CP"},{"key":"e_1_3_7_53_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0219"},{"key":"e_1_3_7_54_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.1379"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-00655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:59:12Z","timestamp":1773863952000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-00655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1200\/PO-25-00655"],"URL":"https:\/\/doi.org\/10.1200\/po-25-00655","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500655"}}